Form 4: Cidara Therapeutics Director Acquires Stock Options Under Benefit Arrangement

Director Joshua Resnick acquired 22,200 stock options in Cidara Therapeutics, though he disclaims beneficial ownership due to an arrangement with RA Capital Management.

Summary

• Joshua Resnick, a director at Cidara Therapeutics, acquired 22,200 stock options on January 3, 2025.
• The options have an exercise price of $26.62 and expire on January 2, 2035.
• The options vest over a three-year period, with one-third vesting on January 3, 2026, and the remaining two-thirds vesting in equal monthly installments over the following two years.
• Resnick disclaims beneficial ownership of these options and the underlying common stock due to an arrangement with RA Capital Management.
• Under this arrangement, any net cash or stock received from the options will offset advisory fees owed by the RA Capital Healthcare Fund to the Adviser.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a stock option grant, which is neither positive nor negative in itself. The arrangement with RA Capital Management is a neutral factor.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, which is common practice in the biotech industry for incentivizing management and aligning their interests with shareholders. The arrangement with RA Capital Management is not unusual for directors who are also affiliated with investment funds.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotech industry.
• Vesting schedules, such as the three-year vesting period described, are typical for these types of grants.
• The arrangement where a director disclaims beneficial ownership due to an agreement with an investment fund is not uncommon, particularly when the director is affiliated with the fund.
• Companies like Amgen, Gilead, and Regeneron also regularly grant stock options to their directors and executives, often with similar vesting schedules and exercise prices.

Related Party Transactions

• The arrangement between Joshua Resnick and RA Capital Management constitutes a related party transaction, where Resnick holds the options for the benefit of the RA Capital Healthcare Fund.

Stakeholder Impact

• The stock option grant has a minimal direct impact on shareholders, as it is a standard form of compensation for directors.
• The arrangement with RA Capital Management may indirectly benefit the fund's investors.

Key Dates

Keywords

stock options, beneficial ownership, director, Cidara Therapeutics, RA Capital Management, vesting, equity securities